Perspective Therapeutics CFO Receives 600K-Share Option Grant for $3.54

Rhea-AI Filing Summary

Perspective Therapeutics insider Joel Sendek, the company's Chief Financial Officer, was granted a stock option on 09/04/2025 to purchase 600,000 shares of common stock at an exercise price of $3.54 per share. The option has an expiration date of 09/04/2035 and becomes exercisable over a four-year vesting schedule: one-fourth vests on 09/04/2026 and the remaining shares vest ratably over the following 36 months, subject to continuous service. After the grant, the reporting person beneficially owns 600,000 underlying shares through the option, held in a direct ownership form. The Form 4 was signed by attorney-in-fact on 09/05/2025.

Positive

• Clear disclosure of option terms including exercise price ($3.54), amount (600,000 shares), vesting schedule, and expiration (09/04/2035)
• Long-term alignment: four-year vesting ties potential upside to continued service and future share-price performance

Negative

• Potential dilution of 600,000 shares if the option is exercised in the future
• No immediate exercise or cash proceeds reported, so there is no current offset to dilution

Insights

Financial Analyst

TL;DR: A 600,000-share option grant to the CFO at $3.54 suggests management equity compensation without immediate exercise.

The award is a standard long-term incentive: a decade-long option term with a four-year vesting schedule beginning one year after grant. This ties potential upside to share-price appreciation over time while delaying exercisability until 09/04/2026. From a capital-structure perspective the grant creates potential future dilution of 600,000 shares if exercised, but there is no immediate cash inflow or share issuance reported. The filing provides clear exercise price, vesting timeline, and expiration, enabling straightforward modeling of potential dilution scenarios.

Corporate Governance Expert

TL;DR: Grant to the CFO follows common governance practice of equity-based pay; vesting conditioned on continued service.

The option vests 25% after one year then ratably over three years, which aligns with common executive retention incentives and ties pay to tenure and future stock performance. The direct ownership form indicates the reporting person holds the option personally. The Form 4 discloses necessary grant terms (exercise price, exercisability date, expiration), supporting transparency for shareholders evaluating executive compensation practices. No additional governance actions or amendments are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sendek Joel

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$3.54	09/04/2025		A		600,000		(1)	09/04/2035	Common Stock	600,000	$0	600,000	D

Explanation of Responses:

1. The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date.

	/s/ Joel Sendek by Chris Nenno, as Attorney-in-Fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joel Sendek (CFO) receive according to the Form 4 for CATX?

The Form 4 reports a grant of a stock option to buy 600,000 shares of Perspective Therapeutics common stock at an exercise price of $3.54 per share.

When does the option become exercisable and when does it expire?

The option vests starting 09/04/2026 (one-fourth) and vests ratably over the next 36 months; the option expires on 09/04/2035.

How many shares does the reporting person beneficially own after the reported transaction?

Following the reported transaction the reporting person beneficially owns 600,000 underlying shares via the option, held directly.

What is the vesting condition noted in the filing?

Vesting is subject to the continuous service of the reporting person as of each vesting date.

Who signed the Form 4 and when was it signed?

The Form 4 was signed electronically by /s/ Joel Sendek by Chris Nenno, as Attorney-in-Fact on 09/05/2025.